Denmark · Delayed Price · Currency is DKK Coloplast Earnings Call Transcripts
Fiscal Year 2026
-
Solid H1 growth driven by core segments, but Wound & Tissue Repair and Biologics face headwinds from U.S. reimbursement changes and weak China demand. Currency and raw material inflation are expected to pressure margins, but guidance remains for 5%-6% organic growth and 5% EBIT growth.
-
Guidance for FY 2025/2026 was revised down due to Kerecis market challenges and currency headwinds, with organic growth now expected at 5%-6%. Chronic Care and Interventional Urology remain strong, while European wound dressings face pricing pressures.
-
Q1 delivered 6% organic revenue growth and 3% EBIT growth in constant currencies, with strong performance in Interventional Urology and ongoing challenges in Kerecis due to Medicare changes. Full-year guidance is maintained, with Kerecis' margin expected to recover and net profit to rise year-over-year.
Fiscal Year 2025
-
The AGM reviewed solid financial results, a new Impact4 strategy, and leadership transitions. Shareholders approved all proposals, including a higher dividend and updated remuneration policy, while management addressed market challenges, supply chain risks, and sustainability goals.
-
Organic growth reached 7% with a 28% EBIT margin before special items, driven by strong chronic care but offset by product recalls and market volatility in other segments. Guidance for 2025-2026 targets 7% organic growth and improved profitability, with continued investment in innovation and efficiency.
-
A new five-year strategy targets 7%-8% organic growth, over 20% ROIC, and enhanced customer-centricity, with major investments in technology, efficiency, and sustainability. Chronic Care and Wound & Tissue Repair are key growth drivers, while China and pricing remain challenges.
-
Organic revenue grew 7% with stable EBIT margin, driven by strong chronic care and Kerecis growth, despite headwinds from product returns in China and FX. New strategy and reorganization aim to boost innovation and value creation, with full-year guidance reaffirmed.
-
Organic growth slowed to 6% in H1, prompting a CEO change and revised guidance. Product recalls and China weakness impacted results, but acquisitions and innovation are performing well. New strategy and financial targets will be unveiled in September.
-
Q1 delivered 8% organic growth and a 27% EBIT margin before special items, with strong performance in Chronic Care, Voice and Respiratory, and Advanced Wound Care. Guidance for FY 2024/25 remains at 8%-9% organic growth and 28% EBIT margin, despite product recall and regulatory delays.
Fiscal Year 2024
-
The AGM reviewed strong 8% organic growth, a 27% EBIT margin, and a DKK 22 per share dividend. Strategic focus remains on four growth platforms, sustainability, and expanding production, while addressing margin pressures and shareholder questions.
-
Organic growth reached 8% for the year, with strong contributions from Chronic Care, Voice and Respiratory Care, and Advanced Wound Care, while Kerecis delivered 35% growth. EBIT margin was 27%, impacted by extraordinary costs and currency headwinds, with guidance for 8%-9% organic growth and a 28% EBIT margin in 2024-25.
-
Delivered 8% organic growth and a 27% EBIT margin before special items, with strong performance in advanced wound care and new product launches. Kerecis integration is on track, but short-term U.S. distribution disruptions and currency headwinds impacted results. Guidance for 8% organic growth and 27-28% EBIT margin is maintained.
-
Strong organic growth, margin recovery, and robust innovation pipeline underpin a positive outlook, with four growth platforms and successful M&A integration driving future performance. Kerecis accelerates U.S. biologics leadership, supported by clinical evidence and high margins.